Permanent Signal

chg-beyond-raw-lit-v1-to-v2

Beyond Raw LIT V2 Pre-Workout: Declared amount change

CONFIRMEDMAJOR materiality, recorded editoriallyReviewed July 29, 2026

Owner/formulator comparison shows L-citrulline 3 g → 5 g, creatine monohydrate 1.5 g → 3 g, electrolytes 45 mg → 250 mg, and new Cognizin 250 mg, Senactiv 50 mg, and AstraGin 50 mg while the 250 mg caffeine system remains.

FormulaSignal observed the earlier state on August 1, 2025 and the newer state on July 23, 2026. Those are observation dates, not the date the brand made the change.

CORRECTED · corr-beyond-raw-lit-window-end-20260729

FormulaSignal corrected this Signal after publication. The finding stands with the corrected content below. Correction accepted July 29, 2026.

What we said: The V1 to V2 change window ended 2025-09-12

What the source showed: Neither endpoint capture was observed on 2025-09-12. The captures on file were observed 2025-08-01 and 2026-07-23, so the stated window end was a rollout date from secondary coverage rather than an observation

Before and after

The material differences.

Declared facts and deterministic calculations remain labeled by their evidence.

Previous state observed
August 1, 2025
New state observed
July 23, 2026
Signal type
Declared amount change
Record category
FORMULA
  • DECLARED FACT COMPARISON

    Electrolytes: 45 mg to 250 mg (+455.6%).

  • DECLARED FACT COMPARISON

    Creatine monohydrate: 1.5 g to 3 g (+100%).

  • DECLARED FACT COMPARISON

    L-citrulline: 3 g to 5 g (+66.7%).

  • Beta-alanine held at 3.2 g across both states.

RECORDED COMMERCIAL CONTEXT

The V2 formula increases declared pump, creatine, hydration, and cognitive-support components while retaining the headline caffeine amount.

Source evidence

Two dated endpoints bound the finding.

Limits and review

What this Signal does not establish.

Limitations

  • The evidence establishes an observation window, not an exact reformulation date.
  • An observation date is the date FormulaSignal read a source. It is not a manufacture date and not the date a change was made.
  • The public sources establish a rollout window, not a manufacturing date or complete retail-channel replacement date. The window is the two observation dates on file. Secondary coverage points to a September 2025 rollout, which is discovery evidence and not an observation we hold, so it does not bound the window. The before state is the formulator's own comparison rather than a dated capture of the V1 label. The 250 mg caffeine total is unchanged while its architecture is not: V1 declared a single 250 mg source and V2 splits it into 200 mg anhydrous plus 50 mg ZumXR extended release.
  • At least one endpoint did not record its claim set in full, so a claim present on one side and absent on the other is non-disclosure rather than removal.
  • At least one endpoint did not record its certification set in full, so a certification present on one side and absent on the other is non-disclosure rather than removal.
Review state
CONFIRMED for public use
Reviewed by
FormulaSignal
Review recorded
July 29, 2026
Evidence basis
Two dated source endpoints
Released
July 29, 2026. Record V1 releases a Signal on the date FormulaSignal records human review. No separate publication timestamp is recorded.